Theravance Biopharma, Inc. (TBPH) AI Stock Analysis

Based in George Town, the Cayman Islands, Theravance Biopharma, Inc. specializes in discovering, developing, and commercializing respiratory medicines across the United States, Europe, and Asia. Its flagship product is YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease. The pipeline includes Izencitinib, a gut-selective pan-JAK inhibitor in Phase IIb/III trials for conditions such as ulcerative colitis and Crohn's disease, and Ampreloxetine, an investigational norepinephrine reuptake inhibitor that completed a Phase III study for neurogenic orthostatic hypotension. It also develops Nezulcitinib, Inhaled ALK5i, and TD-5202.

Annual revenue contracted from $55.3M in FY2021 to $51.3M in FY2022 before expanding to $57.4M in FY2023, $64.4M in FY2024, and $107.5M in FY2025, representing a 5-year revenue CAGR of 8.4%. Operating margin improved from -466.1% in FY2021 to -12.3% in FY2025, while gross margin shifted from -250.1% to 94.9%. Net income stood at $105.9M in FY2025 with an EPS of $1.01, compared to net income of -$56.4M and an EPS of -$0.33 in FY2024. For the trailing twelve months, revenue reached $104.3M with an operating margin of 8.9% and a profit margin of 51.6%, although quarterly revenue fell 20.9% year-over-year in the latest quarter ending June 30, 2026.

As of June 30, 2026, Theravance Biopharma held $387.7M in cash and short-term investments against total debt of $38.6M, resulting in net cash of $349.1M. Liquidity was underscored by a current ratio of 13.54 and a debt-to-equity ratio of 0.13, alongside shareholders' equity of $289.7M. In FY2025, the company generated $238.5M in operating cash flow and $238.5M in free cash flow. Capital allocation in FY2025 included $42,000 for capital expenditures and $4.0M directed toward share buybacks, contributing to a 5-year share count change of -30.1%.

Trading at $17.03 as of September 25, 2026, Theravance Biopharma holds a market capitalization of $884.2M and an enterprise value of $535.1M. The stock trades at a trailing P/E of 16.4x and a forward P/E of 9.7x, below the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its EV/EBITDA of 8.6x is also lower than the peer median of 12.0x, though its price-to-sales ratio of 8.5x exceeds the peer median of 4.1x. Over the past year, the stock returned 23.5% versus 18.5% for the S&P 500, and over five years it returned 142.6% compared to 85.8%.

Wall Street analysts have set a mean price target of $17.67 for Theravance Biopharma, indicating an upside of 3.7% from the last close of $17.03. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $89.9M and an EPS of $0.21. For the following fiscal year, two analysts project revenue of $84.8M and an EPS of $1.27. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is scheduled for November 9, 2026.

This page is an AI-written research summary of Theravance Biopharma, Inc. (TBPH). The text was generated on October 30, 2026 from Quotelinks data as of September 25, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TBPH income statement, TBPH balance sheet, TBPH key metrics, TBPH analyst forecast, TBPH chart. See the TBPH stock overview for the latest quote and news.